Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Functional and structural characterization of mouse Factor H-related B protein unveils a novel dimerization domain shared by FHR-B and FH

  • Martín-Ambrosio, Adrián
  • González-Sanz, Silvia
  • Márquez Tirado, Bárbara
  • Juana-López, Lucía
  • Goicoechea de Jorge, Elena
  • Rodríguez de Córdoba, Santiago
  • Martín Merinero, Héctor
18 p.-14 fig., Factor H-related proteins (FHRs) are found in mice, but their equivalence to human FHRs remains uncertain. This study identifies three FHRs in mouse plasma (FHR-B, FHR-C, and FHR-E) and focuses on characterizing FHR-B. Using purified plasma proteins and recombinant mutants, FHR-B was found to form dimers and bind strongly to C3, C3b, iC3b, and C3dg. It also competes with mouse Factor H (mFH) for binding to C3b-coated surfaces and disrupts mFH regulation in hemolysis assays with sheep and guinea pig erythrocytes. These functions are localized to the C-terminal region and are dependent on FHR-B dimerization. Dimerization occurs through the N-terminal region (SCR1-3), which differs from mFH SCR5-7 by only four amino acids and also shares significant homology with human FHR-3 and human FH SCR5-7. In contrast to FHR-1, AUC experiments indicate that FHR-B dimerization is pH-sensitive, reversible and that the monomers in the dimer present the same head to tail orientation. Mutant analyses revealed that mFH SCR5-7 also forms dimers, but less efficiently than FHR-B. Notably, substituting FHR-B Tyr162 (a key residue homologous to the disease-associated Tyr402 in human FH) for His reduces dimerization. We also found that a recombinant FHR-B with a duplicated dimerization domain formed stable dimers but lacked functional activity. Overall, FHR-B shows structural and functional similarities with various human FHRs, suggesting convergent evolution between mouse and human FHRs. Furthermore, this study reveals a novel dimerization domain shared by FHR-B and mouse FH and illustrates the importance of dimerization and monomer orientation in FHRs activity. It also underlines notable differences between human and mice FHRs that should be further explored before modeling FHR-associated human diseases in mice. Copyright © 2025 Martín-Ambrosio Doménech, González Sanz, Márquez Tirado, Juana-López, Goicoechea de Jorge, Rodríguez de Córdoba and Martín Merinero., The author(s) declare financial support was received for the research, authorship, and/or publication of this article. SR is supported by Spanish “Ministerio de Ciencia, Innovación y Universidades” grant PID2019-104912RB-I00 and RED2022-134750-T, and Autonomous Region of Madrid grant S2022/BMD-7278. EG is supported by “Ministerio de Ciencia, Innovación y Universidades” grant PID2022-138819OB-I00, the European Union’s Horizon 2020 Framework Programme grant 899163 and the Autonomous Region of Madrid grant P2022/BMD-7278., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Severe hypertension with thrombotic microangiopathy: the need for pathogenically targeted treatments

  • Praga, Manuel
  • Caravaca-Fontán, Fernando
  • Cavero, Teresa
  • Fernández-Juárez, Gema
  • Gutiérrez, Eduardo
  • Goicoechea de Jorge, Elena
Malignant hypertension with acute kidney injury or acute kidney disease is a life-threatening condition requiring urgent antihypertensive treatment and which carries a serious risk of kidney function loss. The presence of thrombotic microangiopathy (microangiopathic hemolytic anemia and thrombocytopenia) further challenges the diagnosis and treatment of these patients. As shown by recent studies, a high proportion of patients with complement-mediated thrombotic microangiopathy present with severe and malignant hypertension; however, extreme elevation of blood pressure by itself can induce vascular lesions of thrombotic microangiopathy. To resolve this conundrum, it is essential to rapidly investigate and exclude forms of secondary hypertension (in which hematologic features are rare) and secondary thrombotic microangiopathies, both of which require treatment of the specific underlying etiology. Definitive differentiation of essential hypertension and complement-mediated thrombotic microangiopathy requires complement genetic testing, the results of which usually take weeks to months. In this review, we analyze the clinical and histologic data that would support the diagnosis of complement-mediated thrombotic microangiopathy before the results of genetic tests, prompting the rapid initiation of complement blockers. However, there are numerous unmet gaps in the pathogenesis, diagnosis, and treatment of this disorder that require further research., FC-F is supported by the Instituto Carlos III grant PI24/00140. EGdJ is supported by Ministerio de Ciencia e Innovación grant PID2022-138819OB-I00, European Union’s Horizon 2020 Framework Programme grant 899163, and Autonomous Region of Madrid grant P2022/BMD-7278., Peer reviewed